Update on Emerging Steroid-Based Local Treatments for Noninfectious Uveitis

Chen, Tina H.; Raiji, Veena

doi:10.3928/23258160-20181101-02

Cited by 4 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,21 Drugs injected into the SCS spread circumferentially; when injected into the pars plana region, they expand the SCS and quickly flow posteriorly due to the differential between the IOP and the posterior SCS pressure. 4,[21][22][23][24] The sclera adheres tightly to the ciliary body at the scleral spur, limiting anterior distribution of injectate. 22 In animal models, drugs injected into the SCS were undetectable in the aqueous humor and had negligible dissemination into the vitreous as compared with those given via IVT injection.…”

Section: Scs Administration: An Innovative Drug Delivery Techniquementioning

confidence: 99%

Microinjection via the suprachoroidal space: a review of a novel mode of administration

Ciulla

Yeh²

2022

Am J Manag Care

View full text Add to dashboard Cite

Author disclosure: Dr Ciulla is employed by and owns stock in Clearside Biomedical, which performs research and development using its SCS Microinjector ® . Dr Yeh reports serving on a consultancy or paid advisory board for Bausch + Lomb, Adverum Biotechnologies, and REGENXBIO. Authorship information:Concept and design (TC and SY); acquisition of data (SY); analysis and interpretation of data (SY); critical revision of the manuscript for important intellectual content (TC and SY); supervision (TC).

show abstract

Section: Scs Administration: An Innovative Drug Delivery Techniquementioning

confidence: 99%

Microinjection via the suprachoroidal space: a review of a novel mode of administration

Ciulla

Yeh²

2022

Am J Manag Care

View full text Add to dashboard Cite

show abstract

“…Unfortunately, patients receiving fluocinolone acetonide implants were found to be at higher risk of developing elevated IOP [223]. Interestingly, during late 2018, the FDA approved YUTIQ TM (non-bioerodible intravitreal micro-insert) for sustained delivery of fluocinolone acetonide (0.18 mg) with linear sustained release kinetics up to 3 years for the treatment of chronic non-infectious uveitis [224].…”

Section: Commercially Approved Intraocular Triamcinolone Suspensions Include Triesence ® Andmentioning

confidence: 99%

Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives

Gaballa

Kompella

El-Garhy

et al. 2020

Drug Deliv. and Transl. Res.

153

View full text Add to dashboard Cite

Corticosteroids remain the mainstay of the treatment for various ocular conditions affecting the ocular surface, anterior and posterior segments of the eye due to their anti-inflammatory, anti-oedematous and anti-neovascularization properties. Prednisolone, prednisolone acetate, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, and loteprednol etabonate are amongst the most widely used ophthalmic corticosteroids. Corticosteroids differ in their activity and potency in the eye due to their inherent pharmacological and pharmaceutical differences.Different routes and regimens are available for ocular administration of corticosteroids. Conventional topical application to the eye is the route of choice when targeting diseases affecting the ocular surface and anterior segment, while periocular, intravitreal, and suprachoroidal injections can 3 be potentially effective for posterior segment diseases. Corticosteroid-induced intraocular pressure elevation and cataract formation remain the most significant local risks following topical as well as systemic corticosteroid administration. Invasive drug administration via intracameral, subconjunctival and intravitreal injection can enhance ocular bioavailability and minimize dose and dosing frequency of administration, yet may exacerbate ocular side effects of corticosteroids. This review provides a critical appraisal of the ophthalmic uses of corticosteroid, routes of administration, drug delivery fundamentals and novel ocular implantable steroids delivery systems, factors influencing side effects and future perspectives for ocular corticosteroid therapy.

show abstract